BioWisdom Limited

BioWisdom Limited

February 28, 2008 05:01 ET

Amgen Selects Sofia, BioWisdom's Intelligence Solution for the Healthcare Industry

CAMBRIDGE, UNITED KINGDOM--(Marketwire - Feb. 28, 2008) - BioWisdom Limited (BioWisdom), a leader in the provision of healthcare software and healthcare intelligence for the pharmaceutical industry, today announced that Amgen, Inc. (NASDAQ:AMGN) has signed a multi-year deal for its Sofia™ product to assist in business critical decision-making.

Sofia is used to create Intelligence Networks, a unique format of assertional metadata that liberates knowledge from structured and unstructured data, regardless of its original format. BioWisdom continues to develop the Sofia environment in partnership with some of the world's leading pharmaceutical companies, where the technology is being exploited to address real-world scientific and commercial issues.

"We are very pleased to welcome Amgen as our most recent strategic partner for Sofia" said Gordon Baxter, BioWisdom's CEO. "Creating Intelligence Networks at the scale and accuracy required to support pharmaceutical business decisions requires a robust methodology, powerful automation and stringent quality control.

"Amgen recognizes the critical importance of smarter, better informed, semantically-enabled business systems" said Charlynn Clayton, Director of Research Informatics at Amgen. "We look forward to working closely with BioWisdom, whose experience and leadership in the field of medical ontology is fundamental to our strategy".

ABOUT BIOWISDOM LTD

BioWisdom delivers intelligence for the Healthcare Industry and helps clients to navigate the complex scientific and commercial issues involved in developing successful healthcare products. The company provides a powerful suite of software tools for the formatting, search, visualization and high value analysis of healthcare intelligence. The BioWisdom team combines extensive experience of the pharmaceutical and biotechnology industries with proven expertise in life science software development.

For more information, please visit www.biowisdom.com.

ABOUT AMGEN

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

To learn more about Amgen, please visit www.amgen.com.

Contact Information